Skip to main content
. 2021 Feb 19;16(14):1195–1203. doi: 10.4244/EIJ-D-19-00029

Table 2. Patient characteristics.

Overall (n=308) Ischaemic T-CFC (n=88) Normal T-CFC (n=220) p-value
Age, years 69.0 (61.0-74.0) 72.5 (61.8-75.0) 68.0 (61.0-74.0) 0.078
Male 160 (79.6) 71 (80.7) 175 (79.5) 0.946
Hypertension 212 (68.6) 65 (73.9) 147 (66.8) 0.285
Dyslipidaemia 194 (62.8) 57 (64.8) 137 (62.3) 0.780
Diabetes mellitus 133 (43.0) 49 (55.7) 84 (38.2) <0.001
Current smoker 77 (24.9) 28 (31.8) 49 (22.3) 0.109
Prior PCI 77 (24.9) 17 (19.3) 60 (27.3) 0.190
Prior MI 72 (23.3) 17 (19.3) 55 (25.0) 0.360
LDL cholesterol, mg/dl 94.0 (76.0-111.0) 91.0 (69.0-108.8) 94.5 (78.3-112.0) 0.186
eGFR, mL/min/1.73 m² 69.2 (57.4-83.4) 65.9 (55.5-77.5) 71.5 (58.1-84.2) 0.134
Ejection fraction, % 63.0 (57.0-69.0) 62.0 (56.0-68.0) 63.0 (58.0-69.0) 0.402
Medication
Statin 208 (67.5) 63 (71.6) 145 (65.9) 0.414
ACE-I/ARB 200 (64.7) 59 (67.0) 141 (64.1) 0.720
ß-blocker 143 (46.3) 42 (47.7) 101 (45.9) 0.871
Data are presented as n (%), mean SD, or median (interquartile range). ACE-I: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; eGFR: estimated glomerular filtration rate; LDL: low-density lipoprotein; MI: myocardial infarction; PCI: percutaneous coronary intervention; T-CFC: thermodilution-derived coronary flow capacity